US20120117671A1 - Steatohepatitis-liver cancer model animal - Google Patents
Steatohepatitis-liver cancer model animal Download PDFInfo
- Publication number
- US20120117671A1 US20120117671A1 US13/319,851 US200913319851A US2012117671A1 US 20120117671 A1 US20120117671 A1 US 20120117671A1 US 200913319851 A US200913319851 A US 200913319851A US 2012117671 A1 US2012117671 A1 US 2012117671A1
- Authority
- US
- United States
- Prior art keywords
- human animal
- liver cancer
- steatohepatitis
- administering
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 125
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 78
- 201000007270 liver cancer Diseases 0.000 title claims description 73
- 208000014018 liver neoplasm Diseases 0.000 title claims description 73
- 230000001575 pathological effect Effects 0.000 claims abstract description 50
- 239000000126 substance Substances 0.000 claims abstract description 46
- 238000010171 animal model Methods 0.000 claims abstract description 43
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 38
- 206010061218 Inflammation Diseases 0.000 claims abstract description 35
- 230000004054 inflammatory process Effects 0.000 claims abstract description 35
- 230000001939 inductive effect Effects 0.000 claims abstract description 33
- 210000000056 organ Anatomy 0.000 claims abstract description 30
- 235000009200 high fat diet Nutrition 0.000 claims abstract description 25
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 18
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 17
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 17
- 230000000384 rearing effect Effects 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 44
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 43
- 206010012601 diabetes mellitus Diseases 0.000 claims description 40
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 36
- 238000012360 testing method Methods 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 28
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 27
- 208000035475 disorder Diseases 0.000 claims description 26
- 239000012907 medicinal substance Substances 0.000 claims description 14
- 206010016654 Fibrosis Diseases 0.000 claims description 13
- 210000005229 liver cell Anatomy 0.000 claims description 12
- 239000008177 pharmaceutical agent Substances 0.000 claims description 12
- 238000012216 screening Methods 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 210000004969 inflammatory cell Anatomy 0.000 claims description 10
- 230000008595 infiltration Effects 0.000 claims description 9
- 238000001764 infiltration Methods 0.000 claims description 9
- 102100030122 Protein O-GlcNAcase Human genes 0.000 claims description 8
- 108010055851 Acetylglucosaminidase Proteins 0.000 claims description 7
- 230000007882 cirrhosis Effects 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 16
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 12
- 241000699670 Mus sp. Species 0.000 description 30
- 210000004185 liver Anatomy 0.000 description 14
- 206010019668 Hepatic fibrosis Diseases 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 230000004761 fibrosis Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000013231 NASH rodent model Methods 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 241000725101 Clea Species 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 231100000283 hepatitis Toxicity 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- 206010038923 Retinopathy Diseases 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 235000019784 crude fat Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 201000008383 nephritis Diseases 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 238000013234 NASH mouse model Methods 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 208000033679 diabetic kidney disease Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 230000008807 pathological lesion Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- -1 OCT compound Chemical class 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- PBLNJFVQMUMOJY-JXZOILRNSA-N [(z)-[(3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-ylidene]amino] n-phenylcarbamate Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O\C1=N/OC(=O)NC1=CC=CC=C1 PBLNJFVQMUMOJY-JXZOILRNSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 108010045982 hexosaminidase C Proteins 0.000 description 1
- 230000008935 histological improvement Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/25—Animals on a special diet
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
Definitions
- the present invention relates to steatohepatitis/liver cancer model animals, and uses thereof.
- non-alcoholic fatty liver disease was believed to be a benign disease that does not progress. However, it was revealed that even non-drinkers develop inflammation similar to alcoholic hepatitis and show hepatic fibrosis histology, and now the non-alcoholic fatty liver disease is known as a disease with poor prognosis.
- metabolic syndromes due to obesity, diabetes, or the like have been drawing attention in recent years. It is becoming a common view that nonalcoholic steatohepatitis (NASH) is one of such syndromes.
- NASH nonalcoholic steatohepatitis
- the mechanism remains unclear, and effective methods and/or agents for treating NASH have not been established. This is partly because NASH is due to human lifestyle-related diseases, and thus appropriate experimental animals have not been established.
- Non-patent Document 1 leptin receptor-deficient mice
- Non-patent Document 2 hepatocyte-specific Pten-deficient mice
- Non-patent Document 3 retinoic acid receptor a dominant-negative transgenic mice
- mice induced with a special diet such as a methionine/choline-deficient diet
- the human pathogenesis differs from that in the genetically-modified mice in which a single-gene mutation is responsible for the development and progression of the pathological condition, and is unlikely to be due to only the intake of a particular nutrient. Furthermore, insulin resistance and hepatic fibrosis cannot be simultaneously monitored in these mice. Furthermore, the ALT, an index in serobiochemical analysis, is only slightly elevated in mice that develop fibrosis, and therefore several mouse tissue slices are required to assess their pathological condition. Conversely, the pathological condition is assumed to be different from that of human because ALT is elevated to a markedly high level. Furthermore, the pathological condition recovers spontaneously after treatment. This makes it difficult to test and assess drugs for their efficacy. Thus, for developing methods and agents for treating NASH, it is desirable to establish an experimental animal model that is compatible with the human clinical condition.
- An objective of the present invention is to provide steatohepatitis model animals and liver cancer model animals that exhibit pathological findings similar to those of humans, and uses thereof. More specifically, an objective of the present invention is to provide techniques for producing model animals that develop into fatty liver, steatohepatitis, hepatic fibrosis, liver cirrhosis, and liver cancer from insulin resistance.
- the present inventors conducted dedicated studies to achieve the above-described objectives.
- the present inventors induced insulin resistance by administering an agent for inducing organ inflammation, and induced fatty liver in mice by feeding them with a high fat diet.
- the present inventors successfully developed steatohepatitis in mice.
- a detailed observation of the mice revealed the following pathological findings:
- the above-described pathological findings are characteristic of human nonalcoholic steatohepatitis (NASH). Specifically, by using the above-described method, the present inventors for the first time successfully produced mice that exhibit similar pathological findings as those of human NASH.
- NASH nonalcoholic steatohepatitis
- the NASH animal model produced by the present inventors is different from conventional animal models in the following points:
- the animal model of the present invention is characteristic in that it is produced without genetic modification. Furthermore, the model animals of the present invention unfailingly (100%) develop a pathological condition similar to the progression and prognosis of human NASH at a constant time course, and are the first model animals that exhibit the same course of progression of pathological condition in human. In addition, the model animals of the present invention have a remarkably beneficial effect in that all of insulin resistance, fatty liver, steatohepatitis, hepatic fibrosis, and liver cirrhosis can be observed at the same time.
- the present inventors newly found that the above-described NASH model animals develop liver cancer following liver cirrhosis as they continue the rearing. This is the same change of pathological condition observed in humans.
- the animals prepared by the methods of the present invention are very useful as model animals of human liver cancer.
- Human liver cancer causes the liver surface to bulge.
- conventional model animals for liver cancer which are prepared by administering a chemical substance, develop liver cancer that does not cause bulging of the liver surface.
- model animals of the present invention which are prepared without genetic modification and drug administration, exhibit bulging of the liver surface in a fashion similar to the case of human liver cancer.
- the model of the present invention is a model much closer to human liver cancer.
- liver cirrhosis is not developed by administering chemical substances, while model animals of the present invention develop massive type cord-like liver cell carcinoma.
- infiltration of inflammatory cells and development of liver cancer caused by cirrhosis to displace normal liver cells are observed in the model animals of the present invention.
- liver cancer is macrovesicular fatty liver which shows a pathological condition very similar to that of human NASH.
- the liver cancer develops from hepatic fibrosis and liver cirrhosis.
- the animal model of the present invention is very useful, as it has not been reported previously.
- the present inventors successfully produced model animals for steatohepatitis and liver cancer which show similar pathological findings to those of human, and thereby completed the present invention.
- model animals it is possible to efficiently screen for substances for treating or preventing diseases, and effectively evaluate the efficacy of medicinal substances.
- the present invention relates to model animals which develop into fatty liver, steatohepatitis, hepatic fibrosis, cirrhosis, and liver cancer from insulin resistance, and more specifically, the present invention provides:
- mice To produce experimental animals that develop pathological conditions similar to those of humans, insulin resistance was induced in mice, and fatty liver was induced by feeding them with a high fat diet.
- NAFLD Activity Score (NAS; reference: “Kleiner D E et al., Hepatology. 2005 June; 41(6): 1313-21”) was calculated to assess the pathological features in detail.
- Model animals of the present invention can also be assessed for NASH by using the same NAFLD Activity Score as for human. Thus, the model animals of the present invention are very useful as NASH model animals.
- the present inventors successfully produced steatohepatitis model animals (for example, NASH model animals) and liver cancer model animals that show pathological findings similar to those of humans.
- the present invention provides simple techniques for stably producing animals that develop at an early stage a pathological condition similar to human NASH, which leads to fatty liver, steatohepatitis, hepatic fibrosis, and liver cirrhosis, followed by spontaneous development of liver cancer as a result of progression of the pathological condition, by inducing insulin resistance in experimental animals such as mice, and loading them with a high fat diet.
- diabetic disorders can also be simultaneously observed in the animals.
- the present invention also provides techniques for producing experimental animals that enable the pathological conditions of metabolic syndrome to be observed at the same time.
- the pathological condition does not develop uniformly with aging. It is necessary to monitor the pathological condition of the mice to accurately assess the disease state of NASH, which makes the experiments cumbersome and complicated. Furthermore, the pathological lesions are not always irreversible. This has made the efficacy assessment difficult (Horie Y et al., J din Invest 113: 1774-1783, 2004; Yanagitani A et al., Hepatology 40: 366-375, 2004; Anstee Q M et al., Int J Exp Path 87: 1-16, 2006). Meanwhile, in the model animals of the present invention, the period leading to the mature pathological condition is constant and its progression is irreversible. Thus, the model animals of the present invention can be used to solve the above-described problems.
- the model animals of the present invention can be used in preclinical tests for various therapeutic agents, and are very useful in developing agents and searching for therapeutic targets.
- FIG. 1 shows a result of serobiochemical test in mice of the present invention.
- FIG. 2 shows in photographs a result of fat staining of liver from a mouse of the present invention.
- FIG. 3 shows in photographs a result of immunostaining of liver from a mouse of the present invention.
- FIG. 4 shows in photographs a result of HE staining of liver from a 20-week-old mouse of the present invention.
- FIG. 5 shows a result of HE staining of liver from C57BL/6J in photographs and the NAFLD Activity Score in a graph.
- FIG. 6 shows in photographs a result of F4/80 immunostaining of pancreas and adipose tissue from C57BL/6J.
- FIG. 7 shows in photographs a result of immunostaining of F4/80 and ER-TR7 of 8-week-old BALB/c and C3H/HeN mice.
- FIG. 8 shows photographs of liver cancer in 20-week-old C3H/HeN.
- FIG. 9 shows in photographs reproducible results of NASH model mice reared with other high fat diets.
- FIG. 10 shows in photographs and graphs results of pharmacological tests using the NASH model mice. 1 shows the result of histological analysis in photographs. 2 shows the result of gene expression analysis in photographs.
- FIG. 11 shows the onset of diabetic complications in photographs. 1 shows diabetic nephropathy in photographs, while 2 shows diabetic retinopathy (immunostaining images of new blood vessels; CD31) in photographs.
- the present invention relates to steatohepatitis model animals produced by inducing insulin resistance.
- the present invention provides steatohepatitis model animals (herein sometimes referred to as “model animals of the present invention”) prepared by administering agents for inducing organ inflammation.
- Model animals of the present invention are prepared by administering to experimental animals agents for inducing organ inflammation and then preferably feeding them with high fat diets.
- Animals to be used in the present invention are not particularly limited, as long as they are commonly used as experimental animals. Such animals typically include non-human animals, preferably non-human vertebrates, more preferably non-human mammals, and still more preferably rodents. Examples of animals that can be used to prepare model animals of the present invention specifically include mice, rats, rabbits, dogs, chickens, and monkeys (such animals are sometimes also referred to simply as “experimental animals”).
- the genetic background of the animals to be used to produce model animals of the present invention is not particularly limited; and it is possible to use animals with any genetic background. In general, wild-type animals can be preferably used.
- the agents for inducing organ inflammation are not particularly limited, as long as they have an activity of directly or indirectly inducing inflammation in various organs.
- Organs for inducing inflammation include, for example, pancreas, adipose tissues, and muscle tissues.
- the agents for inducing organ inflammation of the present invention also include agents that directly or indirectly induce inflammation in the peripheral tissues.
- the agents for inducing organ inflammation of the present invention preferably include N-acetyl- ⁇ -D-glucosaminidase inhibitors.
- model animals of the present invention are produced by administering N-acetyl- ⁇ -D-glucosaminidase inhibitors to the above-described experimental animals.
- inhibitors include, for example, streptozotocin and Pugnac.
- nucleic acids having an activity of inhibiting N-acetyl- ⁇ -D-glucosaminidase can also be used as an agent of the present invention.
- nucleic acids include, for example, siRNAs that suppress the expression of the O-G1cNAcase gene (GenBank accession No. NM — 023799.3), antisenses of the gene, and ribozymes that target the gene.
- the dosage form of the agents for inducing organ inflammation is not particularly limited.
- the dosage form includes, for example, subcutaneous administration (subcutaneous injection, etc.), intravenous administration, oral administration, and intraperitoneal administration.
- the dose of the agent to be administered is not limited, and is typically 50 to 500 ⁇ g, preferably 100 to 300 ⁇ g, and more preferably 200 ⁇ g when the agent is streptozotocin.
- the timing for administering the agent is as follows.
- the agent is typically administered one to five days after birth (neonatal period, preferably one to five days old, and more preferably two days old), and preferably two days after birth.
- insulin resistance can be induced by administering the agents.
- the animals are reared to produce model animals of the present invention.
- the animals are preferably fed with a high fat diet.
- Such high fat diets include various general animal diets that are commercially available.
- the major ingredients of the above-described high fat diets include, for example, crude fat, crude protein, crude fiber, crude ash, nitrogen-free extract, and water.
- the high fat diets of the present invention are not particularly limited; however, the content of crude fat is 20% or more, and preferably 30% or more; and the ratio of fat-derived calories to total calories is typically 50% or more, and preferably 60% or more.
- Ingredients to be formulated into the high fat diets include, for example, powdered beef tallow, milk casein, powdered egg white, L-cystine, safflower oil, crystalline cellulose, maltodextrin, lactose, and sucrose. These substances are shown as an example of ingredients of the high fat diets, and are not necessarily contained in the diets.
- high fat diets include, but are not limited to, for example, those that have a higher content of crude fat (for example, higher by about 30% or more) than normal diets.
- An example of such high fat diets include those commercially available as diets for laboratory animals, such as High Fat Diet32 (CLEA Japan Inc.) and D12492 (Research Diets).
- the above-described high fat diet feeding begins typically at the age of 2 to 6 weeks, preferably 3 to 5 weeks, and more preferably 4 weeks.
- the amount of high fat diet given each time is about 3 to 6 g.
- mice are preferably fed with the high fat diet for one week or more.
- Those skilled in the art can appropriately regulate (adjust) the amount of high fat diet depending on the type, size, weight, or such of the experimental animals to be used.
- Fatty liver can be induced by feeding them with a high fat diet.
- the present invention provides steatohepatitis model animals, which comprise the step of inducing fatty liver by administering to the animals agents for inducing organ inflammation and by feeding them with a high fat diet.
- Animals produced by the above-described method develop symptoms of steatohepatitis and are useful as steatohepatitis model animals.
- the model animals of the present invention have the characteristic of simultaneously developing pathological conditions that are observed in animals prepared by the methods of the present invention. It is preferred that the model animals simultaneously develop insulin resistance and/or hepatic fibrosis. However, such pathological conditions are not limited to these examples.
- the model animals of the present invention are characteristic in that the pathological conditions of metabolic syndrome can be observed at the same time, since diabetic disorders (diabetic nephritis, retinopathy, hyperlipidemia, and arteriosclerosis) can be observed simultaneously in model animals of the present invention.
- diabetic disorders diabetic nephritis, retinopathy, hyperlipidemia, and arteriosclerosis
- model animals of the present invention have the characteristic that pathological condition does not recover spontaneously, the animals can be suitably used in testing and assessing drug efficacy.
- the above-described steatohepatitis is nonalcoholic hepatitis (NASH).
- NASH nonalcoholic hepatitis
- the present invention provides nonalcoholic hepatitis (NASH) model animals, which are prepared by administering agents for inducing organ inflammation. The animals steadily develop in a constant time course pathological conditions with similar progression and prognosis to those of human NASH.
- nonalcoholic hepatitis model animals of the present invention have at least one (preferably, all) of the following pathological findings:
- model animals of the present invention are structurally characterized by the above-described pathological morphologies.
- steatohepatitis model animals of the present invention developed liver cirrhosis which led to liver cancer.
- steatohepatitis model animals of the present invention are also useful, for example, as animals (starting materials) for producing liver cirrhosis model animals or liver cancer model animals
- the present invention provides materials for preparing liver cirrhosis or liver cancer model animals, which comprise steatohepatitis model animals of the present invention.
- the present invention provides methods for producing steatohepatitis model animals, which comprise the step of administering agents for inducing organ inflammation to non-human animals
- substances for treating or preventing steatohepatitis can be screened by using model animals of the present invention.
- the present invention provides methods of screening for substances for treating or preventing steatohepatitis, which comprise the steps of:
- Test substances to be used in these methods are not particularly limited.
- such substances include single compounds such as natural compounds, organic compounds, inorganic compounds, proteins, and peptides, as well as compound libraries, expression products of gene libraries, cell extracts, cell culture supernatants, products of fermenting microorganisms, extracts of marine organisms, and plant extracts, but are not limited thereto.
- test substances or medicinal substances of the present invention are not particularly limited; however, they can be administered, for example, orally or by injection.
- a test substance is a protein
- a viral vector carrying a gene encoding the protein may be constructed and can be introduced into model animals of the present invention using their infectability.
- the ameliorating effect on steatohepatitis can be evaluated by determining whether steatohepatitis is ameliorated by assessing the pathological findings of the model animals.
- the pathological findings of steatohepatitis include, for example, the above-described pathological findings (pathological morphologies).
- pathological morphologies pathological morphologies
- “amelioration” means that the symptoms of steatohepatitis are alleviated or restored to normal.
- pathological findings described herein those skilled in the art can appropriately evaluate whether the symptoms of steatohepatitis are ameliorated in the model animals.
- substances that produce the ameliorating effect in the step of (b) above can be selected as substances for treating or preventing steatohepatitis.
- the present invention provides methods for evaluating the efficacy of medicinal substances in ameliorating steatohepatitis, which comprise the steps of:
- medicinal substances that can be evaluated for efficacy by the above-described methods is not particularly limited; and such medicinal substances include, for example, various known pharmaceutical agents (low-molecular-weight compounds, proteins, nucleic acids, or such).
- model animals of the present invention are characterized in showing diabetic disorders (diabetic nephritis, retinopathy, or such) which develop as a complication of diabetes, simultaneously in conjunction with steatohepatitis.
- diabetic disorders diabetic nephritis, retinopathy, or such
- model animals of the present invention are useful as diabetes model animals.
- the present invention provides diabetes model non-human animals prepared by administering agents for inducing organ inflammation.
- Agents for treating or preventing diabetic disorders can be developed by using diabetes model animals of the present invention.
- candidate compounds for treating or preventing diabetic disorders can be screened by administering test substances to diabetes model animals of the present invention, and evaluating their ameliorating effect on diabetic disorders.
- the present invention provides methods of screening for substance for treating or preventing diabetic disorders, which comprise the steps of:
- Model animals of the present invention develop diabetic complications and are thus very useful as model animals, because risks such as side effects discovered at clinical trials can be evaluated at earlier stages by using the model animals.
- the present invention provides methods for evaluating the side effects risks of pharmaceutical agents by using the diabetes model animals of the present invention.
- the present invention relates to methods for evaluating the risk of side effects of pharmaceutical agents for treating or preventing diabetic disorders, which comprise the steps of:
- the present inventors for the first time discovered that as the rearing continues, the above-described steatohepatitis model animals of the present invention develop liver cirrhosis which leads to liver cancer.
- the present invention provides liver cirrhosis model animals and liver cancer model animals which are prepared by continuing to rear the above-described steatohepatitis model animals.
- the present invention relates to liver cancer model animals which are prepared by continuing the rearing of steatohepatitis model animals prepared by administering agents for inducing organ inflammation.
- liver cancer model animals of the present invention subsequently develop liver cirrhosis.
- Liver cancer model animals can be produced by further rearing of the animals.
- the period of rearing after liver cirrhosis has developed is typically, for example, 2 to 20 weeks or more, and preferably 10 weeks or more, when the experimental animal is mouse.
- Liver cancer model animals of the present invention are structurally characterized, for example, by at least one (preferably, all) selected from the following pathological findings (pathological morphologies):
- Liver cancer model animals having the above-described characteristics exhibit the pathological morphologies described above, and thus are structurally different from conventional liver cancer model animals prepared by administering chemical substances (carcinogenic substances).
- Substances for treating or preventing liver cancer can be selected by using the above-described liver cancer model animals of the present invention.
- the above-described methods of the present invention includes methods of screening for substances for treating or preventing liver cancer, which comprise the steps of:
- the therapeutic effect can be appropriately evaluated, for example, using as an indicator the above-described pathological findings of liver cancer.
- the test substance is judged to have therapeutic effect on liver cancer.
- the methods include, for example, those comprising the steps of:
- Pancreatic inflammation was induced in male mice of C57BL6J/JcL, BALB/cByJJcl, and C3H/HeNJcl (CLEA Japan Inc.) two days after birth with cytotoxicity specific to N-Acetyl-beta-D-glucosaminidase (O-GlcNAcase) in pancreatic ⁇ cells (for example, by subcutaneously administering 10 mg/ml streptozotocin (SIGMA) at 20 ⁇ l/head).
- SIGMA streptozotocin
- the mice were reared with a CE-2 diet (CLEA Japan Inc.) and sterile water until four weeks old, and ablactated when they reached the age of four weeks. Then, the mice were reared until 20 weeks old with sterile water and High Fat Diet (CLEA Japan Inc.) or D12492 (Research Diets), which have a higher crude fat content (or by about 30% or more) than normal diet.
- mice of different ages were fasted for 24 hours, they were sacrificed under ether anesthesia, and blood was collected. Each organ was frozen in OCT compound (Sakura Fine Technical), and then sliced into sections for pathological analysis. A serobiochemical test showed that the levels of fasting blood glucose, alanine aminotransferase (ALT), and neutral fat were all higher in this model as compared to the group of normal animals. Thus, the model animals developed insulin resistance and hyperlipemia ( FIG. 1 ). Histologically, severe fatty liver with liver cell ballooning was observed at the age of five weeks. Fat was almost completely eliminated from the liver at the age of eight weeks, and thus the progression of histopathological condition was very similar to that of human burned-out NASH ( FIG. 2 ).
- the pathogenesis of NASH in this mouse model is that pancreatic inflammation triggers chronic inflammation in peripheral tissues such as liver and adipose tissues; insulin resistance develops; and persistent systemic inflammation leads to fatty liver ( FIG. 6 ). Then, the regenerating nodules enlarged as the mice age. Infiltration of inflammatory cells, increase of atypical hepatocytes, and development of cancer to displace normal liver cells were observed at the age of 20 weeks ( FIG. 4 ). Moreover, lesions that are histologically consistent with NASH lesion which leads to liver cancer can also be developed in mice of other lines ( FIGS. 7 and 8 ). NASH lesions were reproducible even if the type of high fat diet was changed ( FIG. 9 ).
- angiotensin receptor antagonist which is an antihypertensive agent
- ARB angiotensin receptor antagonist
- adipose tissue inflammation is also induced at the same time and this potentiates insulin resistance.
- the resulting persistent chronic hyperglycemia causes microangiopathy and such, leading to diabetic complications (diabetic nephropathy, retinopathy, and neuropathy).
- diabetic complications diabetic nephropathy, retinopathy, and neuropathy.
- pathological lesions in other organs were studied in detail.
- glomerular and interstitial fibrosis which are characterized by accumulation of inflammatory macrophages and fibroblasts within and around renal glomeruli were observed at the age of ten weeks, and thus the animals developed diabetic nephropathy ( FIG. 11 ).
- mice of the present invention neovascular blood hyperplasia was observed in the retina, suggesting that the mice developed diabetic retinopathy ( FIG. 11 ).
- the present invention provides NASH model animals which develop fatty liver leading to liver cancer.
- the use of such model animals facilitates the analysis of pathogenesis and pathological condition of human NASH, and development of techniques and agents for treating human NASH.
- the causes of fat accumulation in the liver include alcohol, obesity, diabetes, lipid metabolism abnormality, pharmaceutical agents, and severe malnutrition.
- the causes are roughly categorized as alcoholic and nonalcoholic.
- Alcoholic fatty liver leads to hepatitis, liver fibrosis, and liver cirrhosis.
- nonalcoholic fatty liver has been believed to be a pathological condition that does not progress.
- nonalcoholic fatty liver is a high-incidence disease next to type C hepatitis and alcoholic hepatitis in Europe and the United States.
- the pathological condition was reported to progress into liver cirrhosis and finally liver cancer, which drew attention to the disease.
- the model of the present invention is highly similar to the pathological condition of human NASH in terms of disease progression, and can be used to determine the stage for analyzing the phases of insulin resistance, fatty liver, steatohepatitis, liver fibrosis, and liver cirrhosis, depending on the subject to be treated. Furthermore, by searching for pathogenic factors involved in the progression of each phase, the present invention can also contribute to the development of completely new methods or agents for treating human NASH, hepatic fibrosis, and liver cirrhosis, as well as biomarkers for the diseases. In addition, the present invention is applicable to evaluate pharmacokinetics in NASH lesions. Moreover, the model of the present invention finally leads to liver cancer. Thus, the present invention enables the screening for cancer-suppressing agents or such, investigation of onset mechanism for liver cancer, and pharmaceuticals that target molecules in development of liver cancer.
- diabetic disorders can also be analyzed at the same time.
- the present invention is expected to greatly contribute to the development of methods and agents for liver diseases, elucidation of the relationships among systemic pathological conditions in a subject animal, as well as development of therapeutic methods/agents and biomarkers.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2009/063675 WO2011013247A1 (fr) | 2009-07-31 | 2009-07-31 | Modèle animal du cancer du foie avec stéato-hépatite |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/063675 A-371-Of-International WO2011013247A1 (fr) | 2009-07-31 | 2009-07-31 | Modèle animal du cancer du foie avec stéato-hépatite |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/191,942 Continuation US9596834B2 (en) | 2009-07-31 | 2014-02-27 | Steatohepatitis-liver cancer model animal |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120117671A1 true US20120117671A1 (en) | 2012-05-10 |
Family
ID=43528923
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/319,851 Abandoned US20120117671A1 (en) | 2009-07-31 | 2009-07-31 | Steatohepatitis-liver cancer model animal |
US14/191,942 Active US9596834B2 (en) | 2009-07-31 | 2014-02-27 | Steatohepatitis-liver cancer model animal |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/191,942 Active US9596834B2 (en) | 2009-07-31 | 2014-02-27 | Steatohepatitis-liver cancer model animal |
Country Status (9)
Country | Link |
---|---|
US (2) | US20120117671A1 (fr) |
EP (1) | EP2460403B1 (fr) |
JP (1) | JP5337245B2 (fr) |
KR (2) | KR20120039742A (fr) |
CN (1) | CN102548393B (fr) |
DK (1) | DK2460403T3 (fr) |
ES (1) | ES2738101T3 (fr) |
PL (1) | PL2460403T3 (fr) |
WO (1) | WO2011013247A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017004454A1 (fr) * | 2015-06-30 | 2017-01-05 | Eiger Group International, Inc. | Utilisation de composés de chloroquine et de clémizole pour le traitement d'états pathologiques inflammatoires et cancéreux |
US11612149B2 (en) | 2015-07-10 | 2023-03-28 | Chugai Seiyaku Kabushiki Kaisha | Non-human animal having human CD3 gene substituted for endogenous CD3 gene |
US11793180B2 (en) * | 2016-08-22 | 2023-10-24 | Chugai Seiyaku Kabushiki Kaisha | Gene-modified mouse expressing human GPC3 polypeptide |
US11937587B2 (en) | 2014-11-24 | 2024-03-26 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing humanized CD3 complex |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX369571B (es) * | 2014-04-18 | 2019-11-12 | Lg Chemical Ltd | Composicion para prevenir o tratar enfermedades del higado graso. |
CN104737985A (zh) * | 2015-03-03 | 2015-07-01 | 河北工程大学 | 一种小鼠模拟运输应激模型的建立方法 |
CN105557623A (zh) * | 2015-12-02 | 2016-05-11 | 南京凯斯艾生物科技有限公司 | 一种非酒精性脂肪性肝炎转化成肝癌的实验动物模型 |
SG11201807448WA (en) * | 2016-03-01 | 2018-09-27 | Smc Global Asset Inc | Non-human animals exhibiting degenerative symptom attributed to protein aggregation |
WO2019038908A1 (fr) | 2017-08-25 | 2019-02-28 | 学校法人 日本歯科大学 | Animal modèle non humain pour stéatose hépatique non alcoolique |
CN111248149B (zh) * | 2018-12-03 | 2022-01-28 | 凯斯艾生物科技(苏州)有限公司 | 一种糖尿病伴随重度非酒精性脂肪性肝炎小鼠模型的构建方法 |
CN110338150A (zh) * | 2019-08-11 | 2019-10-18 | 江苏珂玛麒生物科技有限公司 | 一种儿童及青少年肥胖性肾病的动物模型、制备方法、及应用 |
US20220117206A1 (en) * | 2020-10-19 | 2022-04-21 | University Of Florida Research Foundation, Incorporated | Mouse Model of Alcohol-induced Liver Cancer |
CN112674028B (zh) * | 2020-12-30 | 2022-06-28 | 汉姆德(宁波)智能医疗科技有限公司 | 促诱癌剂诱发动物癌症模型建立的方法 |
KR20220158637A (ko) | 2021-05-24 | 2022-12-01 | 연세대학교 산학협력단 | 비알코올성 지방간 인공 조직 모델 |
KR20220168167A (ko) | 2021-06-15 | 2022-12-22 | 연세대학교 산학협력단 | 다중 장기 모델 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070265323A1 (en) * | 2001-06-12 | 2007-11-15 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000270713A (ja) * | 1999-03-23 | 2000-10-03 | Kennetto:Kk | 糖尿病態モデル動物及びその製造方法並びに糖尿病態モデル動物の選定方法 |
JP4271925B2 (ja) * | 2002-10-23 | 2009-06-03 | 株式会社クレハ | 糖尿病モデル動物及びその作製方法 |
KR102244872B1 (ko) * | 2007-12-27 | 2021-04-27 | 가부시키가이샤 티엠이 테라퓨틱스 | 당쇄 관련 유전자, 및 그의 이용 |
-
2009
- 2009-07-31 JP JP2011524600A patent/JP5337245B2/ja active Active
- 2009-07-31 DK DK09847838.1T patent/DK2460403T3/da active
- 2009-07-31 WO PCT/JP2009/063675 patent/WO2011013247A1/fr active Application Filing
- 2009-07-31 US US13/319,851 patent/US20120117671A1/en not_active Abandoned
- 2009-07-31 KR KR1020127005156A patent/KR20120039742A/ko not_active Application Discontinuation
- 2009-07-31 EP EP09847838.1A patent/EP2460403B1/fr active Active
- 2009-07-31 CN CN200980161726.0A patent/CN102548393B/zh not_active Ceased
- 2009-07-31 ES ES09847838T patent/ES2738101T3/es active Active
- 2009-07-31 KR KR1020167010243A patent/KR101761078B1/ko active IP Right Grant
- 2009-07-31 PL PL09847838T patent/PL2460403T3/pl unknown
-
2014
- 2014-02-27 US US14/191,942 patent/US9596834B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070265323A1 (en) * | 2001-06-12 | 2007-11-15 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
Non-Patent Citations (1)
Title |
---|
Kunjathoor et al. J. Clin. Invest. 1996. 97:1767-1773 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11937587B2 (en) | 2014-11-24 | 2024-03-26 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing humanized CD3 complex |
WO2017004454A1 (fr) * | 2015-06-30 | 2017-01-05 | Eiger Group International, Inc. | Utilisation de composés de chloroquine et de clémizole pour le traitement d'états pathologiques inflammatoires et cancéreux |
US10688083B2 (en) | 2015-06-30 | 2020-06-23 | Eiger Group International, Inc. | Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions |
US11612149B2 (en) | 2015-07-10 | 2023-03-28 | Chugai Seiyaku Kabushiki Kaisha | Non-human animal having human CD3 gene substituted for endogenous CD3 gene |
US11793180B2 (en) * | 2016-08-22 | 2023-10-24 | Chugai Seiyaku Kabushiki Kaisha | Gene-modified mouse expressing human GPC3 polypeptide |
Also Published As
Publication number | Publication date |
---|---|
CN102548393B (zh) | 2015-06-03 |
PL2460403T3 (pl) | 2019-11-29 |
KR101761078B1 (ko) | 2017-07-24 |
KR20160048225A (ko) | 2016-05-03 |
US20140178306A1 (en) | 2014-06-26 |
CN102548393A (zh) | 2012-07-04 |
EP2460403B1 (fr) | 2019-05-22 |
EP2460403A4 (fr) | 2013-11-20 |
DK2460403T3 (da) | 2019-08-19 |
ES2738101T3 (es) | 2020-01-20 |
KR20120039742A (ko) | 2012-04-25 |
US9596834B2 (en) | 2017-03-21 |
EP2460403A1 (fr) | 2012-06-06 |
JPWO2011013247A1 (ja) | 2013-01-07 |
WO2011013247A1 (fr) | 2011-02-03 |
JP5337245B2 (ja) | 2013-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9596834B2 (en) | Steatohepatitis-liver cancer model animal | |
Liedtke et al. | Experimental liver fibrosis research: update on animal models, legal issues and translational aspects | |
Guan et al. | GLP-2 receptor in POMC neurons suppresses feeding behavior and gastric motility | |
Asterholm et al. | Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling | |
Abreu-Vieira et al. | Cidea improves the metabolic profile through expansion of adipose tissue | |
McClean et al. | GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet | |
Musso et al. | Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis | |
Gault et al. | Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets | |
Zhuhua et al. | A novel mice model of metabolic syndrome: the high-fat-high-fructose diet-fed ICR mice | |
Arriga et al. | Peroxiredoxin 6 is a key antioxidant enzyme in modulating the link between glycemic and lipogenic metabolism | |
Basseri et al. | Loss of TDAG51 results in mature-onset obesity, hepatic steatosis, and insulin resistance by regulating lipogenesis | |
Han et al. | A role for substance P and acid-sensing ion channel 1a in prolotherapy with dextrose-mediated analgesia in a mouse model of chronic muscle pain | |
JP2012080830A (ja) | ヒト非アルコール性脂肪性肝炎(nash)の非ヒトモデル動物 | |
Matsumoto et al. | Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis | |
Engel et al. | Rodent models of diet-induced type 2 diabetes mellitus: A literature review and selection guide | |
JP2017006022A (ja) | 非アルコール性脂肪肝炎モデル動物の製造方法 | |
US20220288053A1 (en) | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) | |
Chen et al. | Tetramethylpyrazine reduces inflammation in the livers of mice fed a high fat diet | |
Zhao et al. | Type 2 diabetes mellitus non-genetic Rhesus monkey model induced by high fat and high sucrose diet | |
Guzzardi et al. | Leptin resistance before and after obesity: Evidence that tissue glucose uptake underlies adipocyte enlargement and liver steatosis/steatohepatitis in Zucker rats from early-life stages | |
Obydah et al. | Effect of vanillic acid and exercise training on fatty liver and insulin resistance in rats: Possible role of fibroblast growth factor 21 and autophagy | |
JP2009178143A (ja) | 脂肪性肝炎−肝癌モデル動物 | |
US20110044909A1 (en) | Animal model for diabetes | |
Zagmutt et al. | CPT1A in AgRP neurons is required for sex-dependent regulation of feeding and thirst | |
Kitade et al. | Neovascularization and oxidative stress in the progression of non-alcoholic steatohepatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: STELIC INSTITUTE OF REGENERATIVE MEDICINE, STELIC Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YONEYAMA, HIROYUKI;FUJII, MASATO;REEL/FRAME:027616/0713 Effective date: 20120127 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |